Guardion Health Sciences Selected by Malaysian Listed Company to Develop an Immuno-Supportive Formula
February 26 2020 - 7:00AM
Guardion Health Sciences, Inc (“Guardion” or the “Company”)
(Nasdaq:GHSI) announced that Ho Wah Genting Berhad (“HWGB”) a
Malaysian company listed on the Malaysian Stock Exchange
(Industrial Products sector) has selected Guardion to develop an
immune- supportive formula for their consumer base. HWGB has
contracted Guardion and its recently acquired subsidiary
NutriGuard, to develop a proprietary formula to meet the demands of
their customers for an immune-supportive product.
Professor Mark McCarty, the original founder of
NutriGuard, and now a senior scientist consultant to Guardion, is a
leader in the scientific validation of nutrition-based therapies
for potentiating the type 1 interferon response to RNA viruses.
Boosting type 1 interferon response is believed to blunt the
replication of virus cells. Dr McCarty has been tasked with
developing this proprietary formula for HWGB.
The formula is designed to provide both
immuno-supportive and anti-inflammatory benefits to its users. The
formula has not been used nor tested, nor is it intended to
specifically address symptoms of the current COVID-19 virus.
Michael Favish, CEO of Guardion Health Sciences,
stated “We are pleased to partner with Ho Wah Genting Berhad for
the development of a product specifically designed to boost the
immune system capability, i.e. type 1 interferon response, to RNA
viruses.”
Dato’ Aaron Lim, group CEO for Ho Wah Genting
Berhad, commented, “We are anxious to be able to deliver a unique
product that can provide a timely and effective immune response to
our customer base. I would like to thank Guardion Health Sciences
for their assistance and responsiveness to this request and look
forward to introducing this much needed product to the market.”
About Guardion Health Sciences, Inc.
Guardion is an ocular health sciences company
thar develops, formulates, manufacture and distributes
condition-specific medical foods supported by evidence-based
protocols. Guardion’s initial medical food product, Lumega-Z,
addresses a depleted macular protective pigment, a known risk
factor for age-related macular degeneration (“AMD”) and a
significant component of functional vision performance. Guardion
has also developed a proprietary medical device, the MapcatSF®,
which accurately measures the macular pigment density, therefore
providing the only two-pronged evidence-based protocol for the
treatment of a depleted macular protective pigment. Information and
risk factors with respect to Guardion and its business, including
its ability to successfully develop and commercialize its
proprietary products and technologies, may be obtained in the
Company’s filings with the SEC at www.sec.gov.
About VectorVision®
VectorVision® specializes in the
standardization of contrast sensitivity, glare sensitivity, low
contrast acuity, and ETDRS acuity vision testing. Its patented
standardization system provides the practitioner or researcher the
ability to delineate very small changes in visual capability,
either as compared to the population or from visit to visit.
VectorVision®’s CSV-1000 device is considered the standard of care
for clinical trials. VectorVision® is a wholly owned
subsidiary of Guardion.
Guardion has completed development of the
proprietary VectorVision® CSV-2000 standardized contrast
sensitivity test and recently introduced the commercial product to
the marketplace. The CSV-2000 is the only computer-generated vision
testing instrument available that will provide the optical
marketplace with the Company’s proprietary, industry-standard
contrast sensitivity test, along with a full suite of standard
vision testing protocols. The proprietary standardization
methodology incorporated into the CSV-2000 includes a patented
technology known as AcQviz that automatically and constantly
measures and adjusts screen luminance to a fixed standard light
level for vision testing.
About NutriGuard
NutriGuard formulates high-quality,
scientifically credible nutraceuticals, which are designed to
supplement consumers’ diets and assist in the prevention and
management of an array of diseases and conditions. NutriGuard uses
pharmaceutical standards to establish the safety and efficacy of
the products it develops and markets, and also maintains that
commitment through rigorous manufacturing and quality assurance
programs. Guardion plans to increase NutriGuard’s existing customer
base and build on its product platform by making NutriGuard
products available to patients directly and through recommendations
by their physicians.
Forward-Looking Statement Disclaimer
With the exception of the historical information
contained in this news release, the matters described herein may
contain forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. Statements
preceded by, followed by or that otherwise include the words
“believes,” “expects,” “anticipates,” “intends,” “projects,”
“estimates,” “plans” and similar expressions or future or
conditional verbs such as “will,” “should,” “would,” “may” and
“could” are generally forward-looking in nature and not historical
facts, although not all forward-looking statements include the
foregoing. These statements involve unknown risks and uncertainties
that may individually or materially impact the matters discussed
herein for a variety of reasons that are outside the control of the
Company, including, but not limited to, the Company’s ability to
raise sufficient financing to implement its business plan and the
Company’s ability to successfully develop and commercialize its
proprietary products and technologies, including acuMMUNE. Readers
are cautioned not to place undue reliance on these forward- looking
statements, as actual results could differ materially from those
described in the forward-looking statements contained herein.
Readers are urged to read the risk factors set forth in the
Company’s filings with the SEC, which are available at the SEC’s
website (www.sec.gov). The Company disclaims any intention or
obligation to update or revise any forward- looking statements,
whether as a result of new information, future events or
otherwise.
Guardion Health Sciences, Inc.15150 Avenue of Science, Ste.
200San Diego, CA 92128Ph 858.605.9055; Fax
858.630.5543www.guardionhealth.com
Investor Relations Contact:
Porter, LeVay & Rose, Inc.
Michael Porter Telephone: (212) 564-4700E-mail:
mike@plrinvest.com
Matthew AbenanteTelephone: (212) 564-4700 E-mail:
matthew@plrinvest.com
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Sep 2023 to Sep 2024